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Damaged or superfluous cells are typically eliminated by apoptosis. Although apoptosis is a
cell-autonomous process, apoptotic cells communicate with their environment in different
ways. Here we describe a mechanism whereby cells under apoptotic stress can promote
survival of neighbouring cells. We find that upon apoptotic stress, cells release the growth
factor FGF2, leading to MEK-ERK-dependent transcriptional upregulation of pro-survival BCL-
2 proteins in a non-cell autonomous manner. This transient upregulation of pro-survival BCL-
2 proteins protects neighbouring cells from apoptosis. Accordingly, we find in certain cancer
types a correlation between FGF-signalling, BCL-2 expression and worse prognosis. In vivo,
upregulation of MCL-1 occurs in an FGF-dependent manner during skin repair, which reg-
ulates healing dynamics. Importantly, either co-treatment with FGF-receptor inhibitors or
removal of apoptotic stress restores apoptotic sensitivity to cytotoxic therapy and delays
wound healing. These data reveal a pathway by which cells under apoptotic stress can
increase resistance to cell death in surrounding cells. Beyond mediating cytotoxic drug
resistance, this process also provides a potential link between tissue damage and repair.
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The cellular decision to live or die is fundamentally impor-tant in biology. Inappropriate cell survival has been causallylinked to various diseases including cancer and
autoimmunity1. In cancer, many therapies act by engaging
apoptosis, and the degree of apoptotic sensitivity or apoptotic
priming often correlates with therapeutic efficacy1,2. Therefore,
understanding how cancer cells survive therapy should provide
new ways to circumvent this and improve tumour cell elimination.
Mitochondrial apoptosis represents a major form of regulated
cell death3. During apoptosis, mitochondria are permeabilised
through a process called mitochondrial outer membrane per-
meabilisation or MOMP. Widespread MOMP effectively acts as
cellular death sentence by releasing mitochondrial proteins, such
as cytochrome c, that activate caspase proteases leading to rapid
apoptosis3. Even in the absence of caspases, MOMP typically
commits a cell to death, and is thus considered a point-of-no-
return. Consequently, mitochondrial outer membrane integrity is
tightly regulated by pro- and anti-apoptotic BCL-2 family pro-
teins. Anti-apoptotic BCL-2 proteins prevent apoptosis by bind-
ing pro-apoptotic BAX, BAK and BH3-only proteins. During
apoptosis, BH3-only proteins activate BAX and BAK, which
subsequently promote MOMP. This process is exploited by BH3-
mimetics, a new class of anti-cancer drugs1. By binding anti-
apoptotic BCL-2 proteins, BH3-mimetics antagonise BCL-2 pro-
survival function, sensitising cells to apoptosis4. Various BH3-
mimetics have been developed that target select or multiple anti-
apoptotic BCL-2 family members. Amongst them, the BCL-2
specific BH3-mimetic venetoclax5 shows considerable clinical
promise and is approved for the treatment of chronic lympho-
cytic leukaemia (CLL)6 and in combination therapy to treat acute
myeloid leukaemia (AML)7,8. However, in solid tumours, BH3-
mimetics are typically less effective, implying that additional
survival mechanisms must be targeted in order to maximise their
potential.
We set out to identify mechanisms of apoptotic resistance
using BH3-mimetics as tool compounds. Selecting for cells sur-
viving venetoclax treatment, we found that resistance was asso-
ciated with increased anti-apoptotic BCL-2 and MCL-1
expression. Surprisingly, resistance occurred in a non-cell
autonomous manner. We find that under apoptotic stress, cells
can release FGF2. In turn, FGF2 triggers MEK-ERK signalling,
resulting in increased anti-apoptotic BCL-2 and MCL-1 protein
expression and apoptotic resistance. In certain cancer types, we
found a correlation between FGF-signalling, BCL-2 and MCL-1
expression and poorer patient prognosis. Furthermore, we find
FGF-dependent signalling results in upregulation of MCL-1
during wound healing and promotes tissue repair. Together, these
findings unveil a non-cell autonomous mechanism of apoptotic
resistance, where apoptotic stress—via FGF signalling—promotes
cell survival. As we discuss, this process may have wide-ranging
roles in health and disease.
Results
BH3-mimetics and BH3-only proteins upregulate BCL-2 and
MCL-1 causing apoptotic resistance. We initially sought to
define mechanisms of cell death resistance using BCL-2 targeting
BH3-mimetics. For this purpose, we used our recently developed
method called mito-priming9. In this system, cells co-express a
pro-apoptotic BH3-only protein and an anti-apoptotic BCL-2
family member at equimolar levels and are therefore highly
sensitive to BCL-2 targeting BH3-mimetic drugs (Fig. 1a). HeLa
cells were used that stably express tBID together with BCL-2
(HeLa tBID-2A-BCL-2, hereafter called HeLa tBID2A). Cell via-
bility was determined using livecell imaging following venetoclax
treatment using Syto21 to label all cells and propidium iodide to
label dead cells. As expected, the majority of cells died rapidly
following venetoclax treatment, nevertheless some cells failed to
die (Fig. 1b). To investigate the mechanisms of venetoclax resis-
tance, HeLa tBID2A cells were cultured continuously in veneto-
clax to select for resistant cells. Increased expression of pro-
survival BCL-2 family proteins is a common means of apoptotic
resistance10. Indeed, cells that were continuously or intermittently
cultured in venetoclax displayed higher expression of anti-
apoptotic BCL-2 and MCL-1 (Supplementary Fig. 1a). Surpris-
ingly, following culture in regular medium post-venetoclax
treatment, the resistant cells became sensitive to venetoclax
again over time (Supplementary Fig. 1b). This decrease of resis-
tance was accompanied by a decrease of BCL-2 and MCL-1
expression back to basal levels (Supplementary Fig. 1c). We next
investigated whether short-term treatment with venetoclax was
sufficient to promote BCL-2 and MCL-1 upregulation. Indeed,
3 h of venetoclax treatment led to increased levels of BCL-2 and
MCL-1 (Fig. 1c). As before, BCL-2 and MCL-1 levels decreased
following removal of venetoclax, demonstrating a reversible
upregulation (Fig. 1d). This effect was not restricted to veneto-
clax, because an increase in BCL-2 and MCL-1 expression was
also observed following treatment with other BH3mimetics
(navitoclax and ABT-737) (Supplementary Fig. 1d). Given that
venetoclax-induced upregulation of BCL-2 and MCL-1 is rever-
sible, this suggests that it is not genetically based. We noted an
initial resistance of HeLa tBID2A cells cultured in venetoclax to
re-treatment with venetoclax (Supplementary Fig. 1b), pre-
sumably due to increased levels of BCL-2 and MCL-1. Since
increased levels of BCL-2 and MCL-1 were also observed in
response to acute treatment, we investigated whether this was also
sufficient to protect from apoptosis. Indeed, treatment with
venetoclax for 48 h could protect from re-treatment with vene-
toclax and S63845, a specific inhibitor of MCL-111 (Fig. 1e). This
protection was dependent on the increased levels of BCL-2 and
MCL-1, because increasing the dose of venetoclax and S63845
could overcome the resistance (Fig. 1e). The pro-apoptotic pro-
teins BAX and BAK are essential for mitochondrial outer mem-
brane permeabilization (MOMP) during apoptosis12. To
determine the role of apoptosis in the upregulation of BCL-2 and
MCL-1, we generated HeLa tBID2A cells deficient in BAX and
BAK using CRISPR-Cas9 genome editing. As expected, BAX
BAK-deleted HeLa tBID2A cells were completely protected from
mitochondrial apoptosis and caspase activation in response to
venetoclax treatment (Supplementary Fig. 1e, f). Nevertheless,
despite an inability to undergo apoptosis, BAX BAK-deleted
HeLa tBID2A cells still upregulated BCL-2 and MCL-1 following
venetoclax treatment (Fig. 1f, Supplementary Fig. 1g). Similarly,
upregulation of BCL-2 and MCL-1 was also observed when cas-
pase activity was blocked using the caspase inhibitor qVD-OPh
(Fig. 1f). These data demonstrate that while the upregulation of
BCL-2 and MCL-1 requires BH3-mimetic treatment, it occurs
irrespective of apoptosis. Finally, to determine whether upregu-
lation of BCL-2 and MCL-1 was specific to BH3-mimetics, we
examined if a comparable effect could be observed by expressing
BH3-only proteins. Control or BAX and BAK deleted HeLa cells
were transfected with BH3-only proteins (tBID, PUMA, tBID
(BIM BH3, with the BID BH3 domain replaced with the BIM
BH3 domain)) and analysed for MCL-1 expression by western
blot (Fig. 1g, Supplementary Fig. 1h). In all cases, MCL-1
expression was upregulated, indicating that BH3-only proteins
can have similar effects as BH3-mimetics. Collectively, these data
demonstrate that BH3-mimetics and BH3-only proteins can
promote apoptotic resistance by increasing pro-survival BCL-2
protein expression.
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Fig. 1 BH3-mimetics and BH3-only proteins upregulate BCL-2 and MCL-1 causing apoptotic resistance. a Schematic model of the mitoprimed system.
b HeLa tBID2A cells were treated with venetoclax (ven) and imaged over time. Percentage of dead cells was determined by staining all cells with Syto 21
and dead cells with propidium iodide. n= 3 independent experiments; mean values ± s.e.m.; unpaired, two-sided t-test at 24 h. c HeLa tBID2A cells were
treated with 500 nM venetoclax, harvested at the indicated time points and protein expression was analysed by western blot (representative blot of three
independent repeats). d HeLa tBID2A cells were treated for 48 h with 500 nM venetoclax followed by replacement with regular growth medium
(washout). At the indicated times post medium change cells were harvested and protein expression was analysed by western blot (representative blot of
three independent repeats). e HeLa tBID2A cells were treated with or without venetoclax as indicated for 48 h followed by treatment with venetoclax and
the MCL-1 inhibitor S63845. Cell death was then monitored by Sytox Green staining and Incucyte imaging. n= 3 independent experiments; mean values ±
s.e.m. f Control or BAX BAKCRISPR HeLa tBID2A cells were treated with 500 nM venetoclax in combination with 10 μM qVD-OPh as indicated for 48 h,
harvested and protein expression was analysed by western blot (representative blot of three independent repeats). g Control or BAX BAKCRISPR HeLa cells
were transfected with tBID-GFP plasmid, harvested after the indicated times and protein expression was analysed by western blot. Fold change normalised
to loading control is stated below (representative blot of three independent repeats).
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BH3-mimetics and BH3-only proteins can upregulate anti-
apoptotic BCL-2 proteins in a non-cell autonomous manner.
To understand how venetoclax treatment causes upregulation of
BCL-2 and MCL-1, we determined whether increases in protein
or mRNA stability might contribute. HeLa tBID2A cells were
treated with venetoclax for 24 h, after which inhibitors of protein
synthesis (cycloheximide) or transcription (actinomycin D) were
added for varying times. Neither MCL-1 nor BCL-2 protein or
mRNA stability was increased after venetoclax treatment (Sup-
plementary Fig. 2a, b), indicating that mechanisms besides pro-
tein or mRNA stability are likely responsible. Given these results,
we investigated if venetoclax might upregulate BCL-2 and MCL-1
in a non-cell autonomous manner. Control or BAX BAK deleted
HeLa tBID2A cells were treated for 3 h with 500 nM venetoclax,
followed by exchange to regular medium for 45 h. Media from
treated cells was then transferred to recipient cells, which were
examined for BCL-2 and MCL-1 expression after 48 h (Fig. 2a).
Importantly, media from venetoclax treated HeLa tBID2A cells
promoted upregulation of BCL-2 and MCL-1 in recipient cells
(Fig. 2b). Similarly, supernatant from BAX and BAK deficient
cells also promoted MCL1 and BCL-2 upregulation, supporting
earlier findings that cell death is not required for this effect
(Fig. 2b). Supernatant from venetoclax treated cells failed to
induce apoptosis in recipient cells, demonstrating the absence of
potentially residual venetoclax (Supplementary Fig. 2c). Addi-
tionally, media from HeLa tBID2A cells treated with a different
BCL-2 inhibitor, S5574613, also upregulated MCL-1 and BCL-2 in
recipient cells (Supplementary Fig. 2d). To investigate the
mechanism of this non-cell autonomous effect, we first char-
acterised the signal causing upregulation of anti-apoptotic BCL-2
proteins. Supernatant from venetoclax treated HeLa tBID2A cells
was subjected to centrifugal filtration using a filter with a 3 kDa
cut-off. Flow-through and concentrate were added to recipient
cells for 48 h, and MCL-1 and BCL-2 expression was determined
by western blot (Supplementary Fig. 2e). Only the concentrate
(containing molecules above 3 kDa) was capable of increasing
BCL-2 and MCL-1 expression, suggesting that small molecules
such as metabolites and lipids are not responsible. Importantly,
Proteinase K treatment of supernatant from BH3-mimetic treated
cells abolished the ability to upregulate MCL-1 and BCL-2,
consistent with the factor(s) being proteinaceous (Fig. 2c). Finally,
we investigated whether BH3-only proteins can also have a
similar non-cell autonomous effect. HeLa or 293T cells were
transfected with tBID and the supernatant was transferred onto
recipient cells. Consistent with earlier results, supernatant trans-
ferred from tBID transfected cells also caused an up-regulation of
BCL-2 and MCL-1 expression (Fig. 2d, Supplementary Fig. 2f).
Together, these data demonstrate that BH3-mimetics and BH3-
only proteins can upregulate BCL-2 and MCL-1 expression in a
non-cell autonomous manner.
Non-cell autonomous upregulation of anti-apoptotic BCL-2
proteins requires MEK-ERK signalling. We sought to define the
non-cell autonomous mechanism causing anti-apoptotic BCL-2
protein upregulation. For this purpose, HeLa tBID2A cells were
treated with venetoclax together with inhibitors targeting pathways
previously implicated in anti-apoptotic BCL-2 regulation14–17. After
co-treatment for 48 h, cell lysates were probed for BCL-2 and MCL-
1 expression by western blot. Of all the tested inhibitors, only tra-
metinib (a MEK kinase inhibitor18) potently blocked venetoclax
induced BCL-2 and MCL-1 expression (Fig 3a, b). The decrease in
phosphorylation of ERK1/2, a direct target of MEK19, validated
trametinib activity (Fig. 3b). Upregulation of BCL-2 and MCL-1
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Fig. 2 BH3-mimetics and BH3-only proteins can upregulate anti-apoptotic BCL-2 proteins in a non-cell autonomous manner. a Schematic of supernatant
transfer experiments: HeLa tBID2A cells were treated with 500 nM venetoclax for 3 h, followed by exchange to regular growth medium for 45 h.
Supernatant was harvested, filtered and added onto recipient cells before analysis. b HeLa tBID2A cells were treated directly with venetoclax or with
supernatant from untreated or venetoclax treated control or BAX BAKCRISPR cells as described in a. After 48 h cells were harvested and protein expression
was analysed by western blot (representative blot of three independent repeats). c Supernatant from control or venetoclax treated cells was digested with
Proteinase K before addition onto recipient cells and protein expression was analysed by western blot after 48 h (representative blot of three independent
repeats). d Supernatant from HeLa cells transfected with tBID-GFP was collected after 48 h and transferred onto recipient HeLa cells. After 48 h, recipient
cells were harvested and protein expression analysed by western blot. Fold change normalised to loading control is stated below (representative blot of two
independent repeats).
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levels, which could be inhibited by trametinib co-treatment
(Fig. 3c). The upregulation of MCL-1 by BH3-mimetics was not
limited to HeLa cells, since it was also observed in IMR90 lung
fibroblasts and CWR-R1 prostate cancer cells (Supplementary
Fig. 3a, b). We next investigated whether non-cell autonomous
upregulation of BCL-2 and MCL-1 required MEK-ERK signalling.
Trametinib was added to supernatant from venetoclax treated HeLa
tBID2A or CWR-R1 cells before the supernatant was added to
recipient cells. BCL-2 and MCL-1 upregulation was effectively
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effect was transcriptional, because upregulation of MCL-1 RNA in
recipient cells was inhibited by trametinib addition to the super-
natant (Supplementary Fig. 3d). Furthermore, supernatant of
venetoclax treated cells could directly stimulate MEK activity in
recipient cells as determined by increased pERK1/2 levels (Fig. 3e).
To further investigate these findings, we generated ERK1/2 deficient
HeLa tBID2A cells by CRISPR-Cas9 genome editing, hereafter
called ERK1/2CRISPR cells (Fig. 3f). Media from control or ERK1/
2CRISPR deleted cells following venetoclax treatment was transferred
onto control or ERK1/2CRISPR cells, and after 48 h BCL-2 and
MCL-1 expression was determined by western blot. BCL-2 and
MCL-1 expression increased following incubation with media from
venetoclax treated cells or after direct treatment with venetoclax in
control cells but was severely attenuated in ERK1/2CRISPR cells
(Fig. 3f). Finally, we investigated whether MEK signalling, by
enabling BCL-2 and MCL-1 upregulation, contributed to venetoclax
resistance. HeLa tBID2A cells were incubated with venetoclax ±
trametinib for 48 h, after which they were treated with venetoclax
and S63845 and cell viability was determined by Sytox Green
exclusion and Incucyte live-cell imaging (Supplementary Fig. 3e).
Whereas venetoclax pre-treated cells were resistant, trametinib co-
treatment completely abolished this resistance, supporting a func-
tional role for MEK signalling in mediating apoptotic resistance via
BCL-2 and MCL-1 upregulation. Similarly, transfer of venetoclax
treated supernatant conferred resistance to the recipient cells. The
resistance was dependent on BCL-2 and MCL-1 upregulation
because supplementing the venetoclax treated supernatant with
trametinib before addition to recipient cells re-sensitised those cells
to the cytotoxic treatment (Fig. 3g). We next investigated if non-cell
autonomous upregulation of BCL-2 and MCL-1 was specific to
BH3-mimetics or could also be triggered by conventional che-
motherapies. Similar to previous experiments, we treated HeLa cells
with different chemotherapeutic drugs (etoposide, doxorubicin and
paclitaxel) before transferring the supernatant to recipient cells. All
three drugs promoted BCL-2 and MCL-1 upregulation, suggesting
that apoptosis-inducing stresses can generally induce this effect
(Fig. 3h). Supplementing the supernatant with trametinib before
addition to recipient cells prevented upregulation, demonstrating
that MEK-ERK signalling is essential for the upregulation, con-
sistent with our earlier data. Collectively, these data show that
apoptosis-inducing stresses activate MEK-ERK signalling, causing
upregulation of BCL-2 and MCL1 and apoptotic resistance in a
non-cell autonomous manner.
FGF signalling mediates non-cell autonomous upregulation of
BCL-2 proteins. Various ligands can bind to receptors that signal
through MEK-ERK, with receptor tyrosine kinases (RTK) being
prominent activators of this pathway. Therefore, to determine the
paracrine mediator(s) causing BCL-2 and MCL-1 upregulation,
we initially focussed on RTK pathways. To identify potential
ligands present after BH3-mimetic treatment, supernatant from
control or venetoclax treated HeLa tBID2A cells was incubated
with a human growth factor antibody array enabling detection of
41 different growth factors (Fig. 4a). Of the growth factors present
on the array, FGF2 was increased following venetoclax treatment
(Fig. 4a). Upregulation of FGF2 in the supernatant was confirmed
by subsequent ELISA analysis (Fig. 4b). Addition of recombinant
FGF2 to cells at a concentration similar to what we measured in
venetoclax treated supernatant was sufficient to upregulate BCL-2
and MCL-1 expression (Fig. 4c). To directly test the importance
of FGF2 in mediating paracrine upregulation of BCL-2 proteins,
we generated FGF2 deficient cell lines by CRISPR-Cas9 (Sup-
plementary Fig. 4a). Loss of FGF2 completely suppressed the
ability of venetoclax to upregulate BCL-2 and MCL-1 in a para-
crine manner, supporting a key role for FGF2 (Fig. 4d). Con-
sistent with activation of FGF-signalling, known target genes of
FGF receptors (CDX220, DUSP621 and SPRY422) were also
upregulated in response to supernatant from venetoclax treated
cells (Fig. 4e). This upregulation could be blocked by adding
trametinib to the supernatant before addition to recipient cells.
To investigate the requirement of FGF receptors for upregulation
of BCL-2 and MCL-1, we used two different FGFR inhibitors
(AZD4547 and PRN137123,24). Co-treatment of HeLa tBID2A
cells with either inhibitor and venetoclax prevented BCL-2 and
MCL-1 upregulation (Supplementary Fig. 4b). Similarly, super-
natant from venetoclax treated HeLa tBID2A cells supplemented
with FGFR inhibitors prevented upregulation of BCL-2 and
MCL-1 on recipient cells (Fig. 4f). Reduced upregulation of MCL-
1 was also observed upon co-treatment of MRC-5 lung fibroblast
cells with venetoclax and PRN1371 (Supplementary Fig. 4c). The
FGF receptor family is composed of four different receptors25, of
which RNAseq analysis showed that FGFR2 was barely expressed
in the HeLa cells used here (Supplementary Fig. 4d). To deter-
mine which receptors were responsible to signal the upregulation
of BCL-2 and MCL-1 by FGF2, we used RNAi to knock down
their expression individually or in combination. Knocking down
FGFR1 and FGFR3, either individually or in combination, pre-
vented upregulation of BCL-2 and MCL-1 either after direct
treatment (Fig. 4g, Supplementary Fig. 4e) or with venetoclax
treated supernatant (Fig. 4h). In contrast, knockdown of FGFR4
failed to affect BCL-2 and MCL-1 expression (Supplementary
Fig. 4f–h). We next aimed to understand how FGF2 is regulated
Fig. 3 Non-cell autonomous upregulation of anti-apoptotic BCL-2 proteins requires MEK-ERK signalling. a HeLa tBID2A cells were untreated or treated
with 500 nM venetoclax in combination with the indicated inhibitors for 48 h, harvested and protein expression was analysed by western blot
(representative blot of two independent repeats). b HeLa tBID2A cells were untreated or treated with 500 nM venetoclax in combination with 500 nM
trametinib for 48 h, harvested and protein expression was analysed by western blot (representative blot of three independent repeats). c HeLa tBID2A cells
were untreated or treated with 500 nM venetoclax in combination with 500 nM trametinib, harvested and RNA expression was analysed by RT-qPCR.
n= 3 independent experiments; mean values ± s.e.m.; Tukey corrected one-way ANOVA. d Supernatant from untreated or venetoclax treated HeLa tBID2A
cells was supplemented with 500 nM trametinib before addition onto recipient cells. After 48 h of incubation, recipient cells were harvested and protein
expression analysed by western blot (representative blot of three independent repeats). e Supernatant from untreated or venetoclax treated HeLa tBID2A
cells was added onto recipient cells. After the indicated times, recipient cells were harvested and protein expression analysed by western blot. Treatment
with EGF served as a positive control (representative blot of two independent repeats). f Control or ERK1/2CRISPR HeLa tBID2A cells were treated directly
with venetoclax or with supernatant from control or ERK1/2CRISPR HeLa tBID2A cells as indicated before harvesting and western blot analysis for protein
expression (representative blot of three independent repeats). g Supernatant from control or venetoclax treated HeLa tBID2A cells was supplemented with
500 nM trametinib as indicated before addition onto recipient cells. After 48 h of incubation, the recipient cells were treated with 500 nM venetoclax and
500 nM S63845 and survival was monitored by Sytox green exclusion and livecell imaging. n= 3 independent experiments; mean values ± s.e.m.; Tukey
corrected one-way ANOVA. h HeLa cells were treated with the indicated drugs (Etoposide 50 µM, Doxorubicin 2 µM, Paclitaxel 1 µM) for 3 h, followed by
45 h incubation in regular medium. Then the supernatant was harvested, filtered and supplemented or not with trametinib (500 nM) before addition onto
recipient cells. After 48 h, cells were harvested and protein expression analysed by western blot. Fold change normalised to loading control is stated below
(representative blot of three independent repeats).
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in response to BH3-mimetic treatment. A minor, yet significant
increase in FGF2 mRNA was detected in both wild type and BAX
BAK deficient HeLa tBID2A cells following venetoclax treatment
(Fig. 5a), however there was a decrease in FGF2 protein levels
over time (Fig. 5b). Given the lack of increase in FGF2 protein
level, we investigated whether inhibiting transcription in donor
cells affected the upregulation of BCL-2 and MCL-1 in recipient
cells. Supernatant from cells co-treated with venetoclax and
actinomycin D still led to upregulation of MCL-1 and BCL-2 after
transfer (Fig. 5c), suggesting that transcriptional regulation is not
necessary. In contrast, actinomycin D prevented upregulation of
MCL1 in supernatant-treated recipient cells (Fig. 5d), corrobor-
ating transcriptional upregulation of MCL-1 in recipient cells.
These experiments demonstrate that the activation of FGF2 in
response to apoptotic stress is independent of induced expression,
but instead may be due to increased release from the cell. Col-
lectively, these data demonstrate that FGF-signalling, triggered by
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Fig. 4 FGF signalling mediates non-cell autonomous upregulation of BCL-2 proteins. a A growth factor membrane ligand array was probed with
supernatant from control or venetoclax treated HeLa tBID2A cells. Spots for FGF2 are indicated. b Levels of FGF2 were determined in supernatant from
control or venetoclax treated HeLa tBID2A cells by ELISA. n= 3 independent experiments; mean values ± s.e.m.; unpaired, two-sided t-test. c HeLa tBID2A
cells were treated with recombinant FGF2, harvested after 6 h and protein expression analysed by western blot (representative blot of three independent
repeats). d Control or FGF2CRISPR HeLa tBID2A cells were directly treated with venetoclax or the respective supernatant for 48 h as indicated before
harvesting and analysis of protein expression by western blot (representative blot of three independent repeats). e Supernatant from untreated or
venetoclax treated HeLa tBID2A cells was supplemented with 500 nM trametinib before addition onto recipient cells. After 3 h, recipient cells were
harvested and RNA expression of FGF target genes analysed by RT-qPCR. n= 4 independent experiments; mean values ± s.e.m.; *p < 0.0001 compared to
SN Ven; Dunnetts corrected one-way ANOVA. f Supernatant from control or venetoclax treated HeLa tBID2A cells was supplemented with decreasing
doses of FGFR inhibitors as indicated (AZD: 5 µM, 2.5 µM, 1.25 µM; PRN1371: 10 µM, 5 µM, 2.5 µM) before addition onto recipient cells for 48 h and
analysis of protein expression by western blot (representative blot of three independent repeats). g HeLa tBID2A cells were transfected with siRNA
targeting FGFR1 and FGFR3 alone or in combination for 24 h before addition of 500 nM venetoclax, harvesting after 48 h and analysis of protein expression
by western blot (representative blot of three independent repeats). h HeLa tBID2A cells were transfected with siRNA targeting FGFR1 and FGFR3 alone or
in combination for 24 h before addition of control or venetoclax treated supernatant from control cells, harvesting after 48 h and analysis of protein
expression by western blot (representative blot of three independent repeats).
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sufficient for non-cell autonomous upregulation of anti-apoptotic
BCL-2 proteins.
FGF signalling is essential for non-cell autonomous apoptotic
resistance. We next investigated the contribution of FGF-
mediated BCL-2 and MCL-1 upregulation to apoptosis resis-
tance. First, HeLa tBID2A cells were co-treated with venetoclax
and inhibitors of FGF signalling (PRN1371, AZD4547) or MEK
(trametinib). Whereas the venetoclax treated cells were resis-
tant to apoptosis induced by re-treatment with venetoclax and
S63845, cells co-treated with FGF signalling inhibitors were re-
sensitised to apoptosis (Fig. 6a, Supplementary Fig. 5a). As
observed previously, increasing the dose of venetoclax and
S63845 could restore sensitivity to venetoclax pretreated cells.
Next, the potential of FGF signalling to promote non-cell
autonomous apoptotic resistance was investigated. Supernatant
was harvested from venetoclax treated HeLa tBID2A cells and
supplemented with inhibitors of the FGF signalling pathway
before addition onto recipient cells. Consistent with our earlier
data, supernatant from venetoclax treated cells conferred
apoptotic resistance to recipient cells (Fig. 6b, Supplementary
Fig. 5b). Crucially, apoptotic sensitivity was restored upon
inhibition of either FGF or MEK signalling. Again, increasing
the dose of venetoclax and S63845 could kill the venetoclax pre-
treated resistant cells. To investigate this further, we assessed
effects on long-term clonogenic survival. Supporting earlier
data, supernatant from venetoclax treated cells could confer
long-term protection from apoptosis, which was restored by
supplementation of FGF signalling inhibitors (Fig. 6c). To
further investigate these findings, we transferred supernatant
from venetoclax treated control or FGF2 deficient cells
(Supplementary Fig. 4a) and tested survival in response to
venetoclax and S63845. While the supernatant from the wild-
type cells protected from apoptosis, this protection was atte-
nuated in cells treated with supernatant from FGF2 deficient
cells (Fig. 6d). Increasing the concentration of venetoclax and
S63845 could overcome the protective effect of supernatant
from venetoclax treated cells. These data support a model
whereby following apoptotic stress, cells can signal non-cell
autonomous apoptotic resistance by FGF-signalling dependent
on the upregulation of BCL-2 and MCL-1 (Fig. 6e). Finally, we
investigated whether a similar mechanism may be evident in
cancer. Interrogating a total of 25 different TCGA cancer
datasets, we first removed patients with mutations in compo-
nents of the FGFR signalling pathway. These patients might
show an altered activation of the FGF signalling pathway
independent of the non-cell autonomous pathway described in
this work. We next calculated an FGF pathway activation score
by determining the mean expression of ten FGF target genes as
a proxy for activation of FGF signalling. The FGF score was
then correlated with MCL-1 and BCL-2 expression to deter-
mine if increased activation of FGF signalling correlates with
increased levels of prosurvival BCL-2 family gene expression.
Using this approach, we identified several cancer types that
displayed a correlation between FGF activation and BCL-2 and/
or MCL-1 expression (Fig. 6f, Supplementary Fig. 6a, b). Next,
we determined whether this correlation had an influence on
disease progression by stratifying patients into groups based on
FGF score and BCL-2 or MCL-1 expression. Strikingly, in three
out of 25 tested cancer types, survival of the high scoring group
(high activation of FGF signalling and high expression of BCL-2
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Fig. 5 Non-cell autonomous upregulation of BCL-2 proteins is independent of transcription. a HeLa tBID2A cells were treated with 500 nM venetoclax
for the indicated time, RNA was harvested and expression of FGF2 mRNA analysed by qPCR. n= 4 independent experiments; mean values ± s.e.m.;
*p < 0.0001; unpaired, two-sided t-test. b HeLa tBID2A cells were treated with 500 nM venetoclax for the indicated time, harvested and protein expression
analysed by western blot. Fold change normalised to loading control is stated below (representative blot of three independent repeats). c HeLa tBID2A cells
were treated with venetoclax ± actinomycin D for 3 h, followed by 45 h incubation in regular medium. Then the supernatant was harvested, filtered and
added onto recipient cells. After 48 h, recipient cells were harvested and protein expression analysed by western blot (representative blot of three
independent repeats). d HeLa tBID2A cells were treated with venetoclax for 3 h, followed by 45 h incubation in regular medium. Then the supernatant was
harvested, filtered, supplemented with actinomycin D as indicated and added onto recipient cells. After 3 h, recipient cells were harvested and protein
expression analysed by western blot (representative blot of three independent repeats).
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low scoring group (Fig. 6f, Supplementary Fig. 6a, b). These
data suggest that FGF-mediated resistance might have a pro-
tective effect on cancer cell survival and therefore worsen
prognosis.
FGF signalling induces MCL-1 in the skin and regulates wound
healing dynamics. Oncogenic processes are often subverted
homoeostatic mechanisms. We therefore sought to define phy-
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expression. Because our data are consistent with a model in which
stressed cells can alert the microenvironment to increase their
threshold against apoptosis, we decided to test this hypothesis in a
physiologically relevant and experimentally tractable model. In
the epidermis, apoptosis has been found to play an important role
in skin repair26,27. Notably, re-epithelization of the skin relies
heavily on FGF signalling28. We therefore set out to examine
whether FGF signal transduction might also modulate MCL-1
expression in the skin upon wound infliction. We hypothesised
that an injured tissue might increase its apoptotic threshold to
limit damage due to cell death in areas that require regeneration.
This increased resistance to apoptosis could potentially protect
against excessive cell death which could hinder tissue regenera-
tion. Indeed, subjecting the dorsal skin of mice to 1 cm2 full-
thickness excisional wounds promoted upregulation of MCL-1 in
keratinocytes in the vicinity of the wound (Fig. 7a). We next
examined whether inhibition of FGF signalling affected MCL-1
expression by utilising the FGFR inhibitor AZD4547 and the
MEK inhibitor trametinib. We administered the inhibitors for
four consecutive days by subcutaneous injection prior to infliction
of the wound and harvested the skin three days post wound
infliction (PWI). Our results indicate that administration of either
inhibitor dramatically decreased the number of MCL-1+ cells
following injury (Fig. 7b, c), suggesting that upregulation of
MCL-1 in response to skin injury is dependent on FGF signalling.
To investigate the physiological role of FGF mediated MCL-1
upregulation, we monitored wound closure dynamics. For this
aim, we inflicted full-excisional wounds on dorsal skins of control
or inhibitor treated mice and evaluated wound coverage at
specific time points PWI (Supplementary Fig. 7a). In control
mice, the wound size was reduced by ~40% after just one day,
whereas in inhibitor treated mice no coverage was seen at this
time point (Fig. 7d). This delay was accompanied by a decreased
area of re-epithelization (Fig. 7d, Supplementary Fig. 7b, c). To
examine the contribution of epidermal keratinocytes to the
observed phenotypes, we next evaluated proliferation in the
wound bed. We harvested wounds at three and seven days PWI.
FGFR and MEK-inhibition resulted in decreased proliferation
evident by Mcm2 and Ki67 immunostaining (Supplementary
Fig. 7b, d, e). The attenuation in wound closure phenotypes seen
upon FGFR-inhibition could potentially be facilitated via
decreased basal cell expansion and suprabasal migration capacity.
Elegant studies have shown that in early stages of wounding
healing the leading edge of the wound is mostly composed of
non-proliferative migratory cells that can drive rapid re-
epithelialization29,30. Our analysis revealed that FGFR-inhibited
wounds displayed a less pronounced leading edge by seven days
PWI, when compared to control (Supplementary Fig. 7b, c).
These findings suggest that suprabasal keratinocytes may also
contribute to the attenuated wound healing phenotypes seen
upon inhibition of FGF receptors and MEK. Our data indicate
that FGF signalling induces the expression of MCL-1 in the skin
and affects the contribution of both basal and suprabasal
keratinocytes to the wound repair process. Overall, our results
suggest a mechanism in which cells protect their tissue integrity
by increasing the apoptotic threshold in response to stress by
FGF2 mediated upregulation of pro-survival proteins.
Discussion
Innate or acquired resistance to cell death is of fundamental
importance in health and disease. For instance, evasion of
apoptosis can both promote cancer and inhibit treatment
response, leading to tumour relapse31. To understand how cells
can resist cell death, we used BCL-2 targeting BH3-mimetics as
tool compounds. Unexpectedly, we uncovered a non-cell auton-
omous mechanism that enables apoptotic resistance. We found
that upon apoptotic stress, cells can release the growth factor
FGF2. By activating MEK-ERK signalling, FGF2 upregulates anti-
apoptotic BCL-2 protein expression32,33 in neighbouring cells,
protecting against apoptosis. Importantly, resistance can be
overcome by co-treatment of BH3-mimetics with FGFR-inhibi-
tors, demonstrating the functional significance of the pathway.
Accordingly, in an in vivo injury model inhibition of FGFR sig-
nalling prevents MCL-1 upregulation, apoptosis and successively
wound healing. Finally, we describe a correlation between
increased FGF signalling, anti-apoptotic BCL-2 protein expres-
sion and poor patient prognosis, suggesting its relevance in vivo.
As we discuss further, the process we describe here, where cell
death promotes life, may have various pathophysiological
functions.
Most cancer therapies work by killing tumour cells, conse-
quently resistance to cell death profoundly impacts on therapeutic
efficacy31. Typically, cancer cells can evade apoptosis through
inactivating mutations in pathways that sense damage or activate
cell death31. For instance, in chronic lymphocytic leukaemia
(CLL), BCL-2 mutations have recently been reported that render
BCL-2 unable to effectively bind the BH3-mimetic venetoclax,
causing apoptotic resistance34–37. The resistance mechanism we
report here is not mutation based, but instead is due to dying cells
releasing FGF2 that causes transient apoptotic resistance in
Fig. 6 FGF signalling is essential for non-cell autonomous apoptotic resistance. a HeLa tBID2A cells were treated with 500 nM venetoclax in
combination with RTK pathway inhibitors (AZD4547 (5 μM), PRN1371 (10 μM) or trametinib (500 nM)) as indicated for 48 h. Then the cells were treated
with the indicated concentrations venetoclax + S63845 and cell survival was monitored by Incucyte. Heatmap colours show cell death at 24 h (mean from
n= 3 independent experiments), corresponding survival curves are shown in Supplementary Fig. 5a. b HeLa tBID2A cells were incubated with 500 nM
venetoclax treated supernatant supplemented with RTK pathway inhibitors (AZD4547 (5 μM), PRN1371 (10 μM) or trametinib (500 nM)) as indicated
before addition onto recipient cells for 48 h. Then the cells were treated with the indicated concentrations venetoclax + S63845 and cell survival was
monitored by Incucyte. Heatmap colours show cell death at 24 h (mean from n= 3 independent experiments), corresponding survival curves are shown in
Supplementary Fig. 5b. c HeLa tBID2A cells were plated at low density (1000 cells per 6 well) and incubated with 500 nM venetoclax-treated supernatant
supplemented with RTK pathway inhibitors (AZD4547 (5 μM), PRN1371 (10 μM) or trametinib (500 nM)) as indicated for 48 h. Cells were then treated
with 2.5 μM venetoclax + S63845 for another 48 h before replacement with regular growth medium. After an additional 5 days colonies were visualised by
crystal violet staining and quantified. n≥ 3 independent experiments; mean values ± s.e.m.; *p < 0.05 compared to all other treatments; Tukey corrected
one-way ANOVA. d Control or FGF2 deficient cells were treated for 3 h with 500 nM venetoclax followed by 45 h regular medium. Then the supernatant
was harvested and added to control cells for 48 h. After that, the cells were treated with venetoclax + S63845 with the indicated doses and survival
monitored by Incucyte. n= 3 independent experiments; mean values ± s.e.m.; *p < 0.05 compared to venetoclax treatment at 24 h; Tukey corrected one-
way ANOVA. e Working model. f Pearson correlation between FGF Score and BCL-2 (upper left) or MCL-1 (lower left) in the TCGA Thymoma dataset (±
s.e.m, 105 patients). FGF score, FGF receptor target gene and BCL-2 (upper middle) or MCL-1 (lower middle) expression in the TCGA Thymoma dataset.
Survival of TCGA Thymoma patients stratified by FGF score and BCL-2 (upper right) or MCL-1 (lower right) expression (p value was calculated with a log-
rank test).
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surrounding cells. This mechanism fits the concept of persistence,
which has emerged to explain transient, non-heritable resistance
of tumour cells to therapy38. Cancer cells that transiently evade
cell death, called persister cells, blunt the effectiveness of che-
motherapy and provide a cell pool from which drug-resistant
tumours may arise. The mechanism we describe herein represents
a non-cell autonomous way of generating persistence (via FGF2
release) that requires activation of the core apoptotic pathway.
Suggestive of its relevance in vivo, we find that in certain cancer
types there is a correlation between FGF-signalling, anti-apoptotic
BCL-2 protein expression and poor prognosis. Importantly, we
find that inhibition of FGF receptor signalling or of downstream
MEK-ERK signalling greatly impedes the ability of stressed cells
to promote survival in a non-cell autonomous manner. Our data
show that apoptotic resistance is transient lasting multiple days,
after which cells become sensitised again to BH3-mimetics.
Extrapolating these findings to a clinical setting, one possibility
may be to combine apoptosis inducing cancer therapy with FGFR
inhibitors. Additionally, our data suggest that intermittent dosing
of apoptosis inducing therapies, employing so-called drug holi-
days, may help circumvent apoptotic resistance.
Some molecular and cellular mechanisms are known to be
shared by both wounds and cancers, bringing forward the con-
cept of tumours as over-healing39. Tissue integrity is essential for
the proper functioning of any multicellular organism. To main-
tain this integrity, breaches have to be refilled, for instance by
increased migration and proliferation. Epithelial tissue like skin is
often subjected to injury, and efficient repair is necessary to close
the wound and to restore proper barrier functions. This wound
repair is facilitated by growth factors like FGF2 to promote cell
proliferation and angiogenesis40,41. Interestingly, secretion of
FGF2 was shown to be induced by shear stress42, and activation
of ERK signalling is observed in several instances of tissue
regeneration43,44. Pro-survival ERK signalling engaged by EGF
released by apoptotic cells has recently been found to promote
tissue integrity45,46. Importantly, while we find that FGF2 can be
released from viable cells under conditions of apoptotic stress,
EGF release required apoptosis. This highlights that pro-
apoptotic signalling can engage multiple pro-survival mechan-
isms. The role of BCL-2 proteins in skin injury has not been
extensively studied, however MCL-1 seems to be involved in
keratinocyte survival and differentiation47. Our data now provide
a potential connection between FGF2 and MCL-1 in wound
healing: In response to cell stress due to injury, cells secrete FGF2
to induce pro-survival MCL-1 expression in neighbouring cells
and to increase their apoptotic threshold. Increasing resistance to
death in this setting might have several reasons, for example to
limit the sustained damage by preventing extensive cell death or
to promote regeneration of the tissue by protecting heavily pro-
liferating cells from death. Inhibiting FGF signalling during
wounding or decreasing the apoptotic threshold with BH3-


















































































Fig. 7 FGFR and MEK inhibition decreases MCL-1 expression and hinders wound repair. a H & E and immunostaining of MCL-1 in unwounded skins and 3
or 7 days post wounding (PWI). Representative image of n= 15 mice, Scale bar: 200 µm, Inset 50 µm. The wound edge is indicated with a black broken
line. b H & E and immunostaining of MCL-1 in skins 3 days post wounding in DMSO or inhibitor treated mice as indicated. Representative image of n= 15
mice per group, Scale bar: 200 µm. The wound edge is indicated with a black broken line. c Quantification of MCL-1 positive cells in the area surrounding
the wound site. n= 15 mice per group, each dot represents an individual mouse, mean values ± s.e.m.; *p < 0.0001 compared to DMSO; Tukey corrected
one-way ANOVA. d Quantification of dorsal wound coverage in DMSO or inhibitor treated mice over a 7-day period. N≥ 2 mice per group, each dot
represents an individual mouse, mean values ± s.e.m.; Tukey corrected one-way ANOVA at day 7.
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for the future would be to examine how signals released from
apoptotic cells can be harnessed to facilitate tissue regeneration.
A remaining question is how apoptotic stress leads to FGF2
release in dying cells. FGF2 is secreted from cells in a non-
conventional manner that remains to be fully elucidated48.
Importantly, while FGF2 release occurs during caspase-
dependent apoptosis, it is not dependent on apoptosis - neither
inhibition of caspase function nor MOMP prevents FGF2 release.
This suggests that neutralisation of anti-apoptotic BCL-2 proteins
exerts a non-lethal signalling function, leading to FGF2 release.
Indeed, a variety of non-apoptotic functions for BCL-2 have been
reported previously, for instance roles in calcium signalling or
metabolism49. Alternatively, BH3-only proteins may be respon-
sible for this FGF2 release. FGF2 is secreted in a non-canonical
manner, which involves its binding to PI(4,5)P2 at the plasma
membrane followed by insertion of FGF2 oligomers through the
membrane50. Although tBID was described to be able to interact
with various membranes like artificial liposomes51, lysosomes52
or mitochondria53, it remains to be determined if this function of
tBID can be extended to FGF2 secretion.
Our data further emphasise that cell death exerts a plethora of
non-cell autonomous effects. These include context dependent
pro-proliferative, inflammatory and apoptotic activities54–56. The
mechanism we describe here represents an FGF-driven pro-sur-
vival effect of apoptotic stress. As discussed, this effect may have
important implications for dictating therapeutic efficacy of
apoptosis-inducing cancer therapy. Beyond this, we show that
apoptotic stress induced survival signalling may also have a
physiological role linking tissue stress to tissue repair.
Methods
Cell lines and chemicals. HeLa and 293T cells were purchased from ATCC, HeLa
tBID2A BCL-2 were previously described9, MRC5 and IMR90 cells were a gift from
Peter Adams, Beatson Institute, and CWR-R1 cells were a gift from Arnaud
Blomme, Beatson Institute. Cell lines were not authenticated. Cells were regularly
tested negative for mycoplasm. HeLa, HeLa tBID2A BCL-2 cells9, IMR90, MRC-5
and 293 T cells were cultured in DMEM high‐glucose medium supplemented with
10% FCS and 2mM glutamine. CWR-R1 cells were cultured in RPMI high‐glucose
medium supplemented with 10% FCS and 2mM glutamine. MRC5 and IMR90
cells were cultured in 3% oxygen. To select for venetoclax resistant cells, HeLa
tBID2A BCL-2 cells were cultured continuously in the indicated dose of venetoclax
for 14 days or cultured for 8 h in venetoclax followed by 16 h normal medium daily.
The following drugs and chemicals were used: ABT-199/venetoclax (AdooQ
BioScience, A12500-50), ABT-263/Navitoclax (ApexBio, A3007), ABT-737
(ApexBio, A8193), Actinomycin D (Calbiochem, 114666), AZD4547 (Selleck,
S2801), Chir99021 (GSK3 inhibitor, final concentration 3 µM, Gift from D. Mur-
phy), Cycloheximide (Sigma, 1810), Doxorubiucin (Sigma D1515), EGF (Sigma,
E4127), Etoposide (Sigma, E1383), FGF2 (Thermo, PHG0263), GSK690693 (AKT
inhibitor, final concentration 1 uM, gift from Daniel Murphy, University of
Glasgow), Paclitaxel (Sigma, T7191), PRN1371 (Selleck, S8578), Propidium iodide
(Sigma, P4170), Proteinase K (Thermo, 25530049), Pyr41 (E1 Ubiquitin ligase
inhibitor, final concentration 50 µM, Sigma, N2915), qVD-OPh (AdooQ
BioScience, A14915-25), Rapamycin (mTOR inhibitor, final concentration 1 µM,
Santa Cruz, sc-3504), S55746 (ProbeChem, PC-63502), S63845 (Chemgood, C-
1370), Sytox Green (Thermo, S7020), Syto 21 (Sigma, S7556) and trametinib (MEK
inhibitor, Cambridge Bioscience, HY-10999).
Lentiviral transduction. CRISPR-Cas9‐based genome editing was performed using
LentiCRISPRv2‐puro (Addgene #52961) or LentiCRISPRv2‐blasti9 using the fol-
lowing guide sequences: hBAX, 5′-AGTAGAAAAGGGCGACAACC-3′; hBAK,
5′-GCCATGCTGGTAGACGTGTA-3′; hERK1, 5′-CAGAATATGTGGCCACA
CGT-3′; hERK2, 5′-AGTAGGTCTGATGTTCGAAG-3′; hFGF2.1, 5′-TATGCA
AGTCCAACGCACTG -3′ and hFGF2.2, 5′-CGAGCTACTTAGACGCACCC-3′.
For stable cell line generation, 5*10^6 293FT cells were transfected in 10 cm
dishes using 4 μg polyethylenimine (PEI, Polysciences) per μg plasmid DNA with
lentiCRISPR_V2 (Addgene 52961): gag/pol (Addgene 14887): pUVSVG (Addgene
8454) at a 4:2:1 ratio. After 48 and 72 h of transfection, virus containing
supernatant was filtered, supplemented with 1 μg/ml polybrene (Sigma) and added
to 50.000 recipient cells in a 6 well plate. Selection with appropriate antibiotics
(1 μg/ml puromycin (Sigma) or 10 μg/ml blasticidin (InvivoGen)) was started 24 h
after the last infection and continued for one week57.
Supernatant assays. Generally, cells were treated for 3 h with 500 nM venetoclax,
then the medium was replaced with regular growth medium. After an additional
45 h the supernatant was harvested, filtered and added onto recipient cells. For
Proteinase K treatment, supernatant was treated with 200 μg/ml Proteinase K for
60 min at 50 °C, followed by 5 min at 95 °C. After cooling down, the treated
supernatant was added to recipient cells. For centrifugal filtration, supernatant was
filtered and added into an Amicon Ultra 15 ml tube (Merck) with a 3 kDa cut-off.
After spinning at 4000 g for 60 min, the concentrate was diluted with regular
growth medium to its original volume and the concentrate or the flowthrough was
added onto recipient cells. The FGF2 ELISA was performed using the Human FGF-
basic ELISA MAX Deluxe (Biolegend) according to the manufacturer’s instructions
after 50x concentration of the supernatant by centrifugal filtration (see above). The
final FGF2 concentration was determined using a standard of recombinant FGF2,
taking into account the concentration step.
Plasmid and siRNA transfection. For plasmid transfection, Lipofectamine 2000
was used according to the manufacturer’s instructions. Transfection of siRNA was
performed using Oligofectamine according to the manufacturer’s instructions. The
following siGENOME SMARTpool siRNAs from Dharmacon were used: Non-
targeting, D0012061305; hFGFR1, M-003131-03-0005; hFGFR3, M-003133-01-
0005 and hFGFR4, M-003134-02-0005.
Western blotting. Cell lysates were prepared using lysis buffer (1% NP-40, 0.1%
SDS, 1 mM EDTA, 150 mM NaCl, 50 mM Tris pH7.5, supplemented with Com-
plete Protease Inhibitors (Roche) and PhosSTOP (Roche)). Protein concentration
was determined with Bio-Rad Protein Assay Dye (5000006), and lysates were
separated by SDS-PAGE followed by blotting onto nitrocellulose membranes and
incubation with primary antibody (1:1000 in 5% milk) overnight. After washing in
TBS/T and incubation with secondary antibody (Li-Cor IRDye 800CW donkey
anti-rabbit, 926-32213, dilution 1:20000), blots were developed on a Li-Cor
Odyssey CLx system and acquired using Imagestudio (Li-Cor). The following
primary antibodies were used: Actin (A4700, Sigma), BAK (12105, Cell Signaling),
BAX (2772, Cell Signaling), BCL-2 (4223, Cell Signaling), ERK1/2 (4695, Cell
Signaling), basic FGF (20102, Cell Signaling), FGFR1 (9740, Cell Signaling), FGFR3
(4574, Cell Signaling), FGFR4 (8562, Cell Signaling), GFP (In house), HSP60 (4870,
Cell Signaling), MCL-1 (5453, Cell Signaling), pERK1/2 (4370, Cell Signaling),
Caspase 3 (9662, Cell Signaling), Caspase 9 (9502, Cell Signaling), PARP1 (9532,
Cell Signaling) alpha-Tubulin (T5168, Sigma) and cleaved Caspase 3 (9664, Cell
Signaling).
Quantitative RT-PCR. RNA from cultured cells was isolated with the GeneJET
RNA purification kit according to the manufacturer’s instructions. cDNA synthesis
was performed according to the manufacturer’s instructions using the High
Capacity cDNA Reverse Transcription Kit (Thermo), and qPCR was performed
with the Brilliant III Ultra‐Fast SYBR Green qPCR Master Mix (Agilent Tech-
nologies) on a QuantStudio 3 machine (Applied Biosystems) with the following
programme: 3 min at 95 °C, 40 cycles of 20 s at 95 °C, 30 s at 57 °C, 30 s at 72 °C
and a final 5 min at 72 °C. Results were analysed using the 2–ΔΔCt method. Primer
sequences can be found in Supplementary Table 1.
Cell death assays. Short-term cell death was determined with an Incucyte FLR or
Zoom imaging system (Essen Bioscience)58. Cells were treated as indicated in the
Figure legend together with 30 nM Sytox green and imaged every 1 or 2 h. Analysis
was performed using the Incucyte software and the number of dead (Sytox green
positive) cells was normalised to the confluency at t= 0. Alternatively, cells were
pre-treated for 1 h with 50 nM Syto 21, followed by cytotoxic treatments as indi-
cated together with 5 μg/ml propidium iodide. Long-term colony formation assay
was performed by plating 1000 cells per 6 well and treatment as described in the
Figure legend. After 48 h of treatment with supernatant, the medium was changed
to 2.5 μM venetoclax/S63845. Medium was changed to regular growth medium
after an additional 48 h, and resulting colonies were stained with crystal violet after
an additional 5 days. Cell death analysis via FACS was performed using Annexin V
- propidium iodide staining59. In short, treated cells were harvested and stained
with 5 μg/ml propidium iodide and Annexin V (Biolegend) in Annexin V-binding
buffer (10 mM Hepes pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) for 15 min. Flow
cytometry was conducted on a BD FACSCalibur machine with BD CellQuest
software and analysed using Flowing software; cells negative for propidium iodide
and Annexin V were considered alive.
Membrane ligand array. Supernatant was harvested from HeLa tBID2A cells as
described above and used to probe a Human Growth Factor Antibody Array
(Abcam, ab134002) according to the manufacturer’s instructions.
Bioinformatic analysis. Mutation, survival and gene expression data (Thymoma
TCGA Firehose Legacy) was downloaded from cBioPortal (www.cbioportal.org).
Samples with alterations (Deletions, mutations or amplifications) in components of
the FGFR signalling pathway (FGFR1, FGFR3, GRB2, FRS2, SOS1, HRAS, RAF1,
MAPK1, MAPK3) were removed. The FGF score was determined by averaging the
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expression of the FGF2 induced gene set (CDH2, CDX4, FES, FGF2, FRS2, FYN,
HOXA10, INHBA, MAP2K1, MAPK8, MMP7, PF4, RUNX2, SERPINF1) from the
Harmonizome database (https://maayanlab.cloud/Harmonizome/gene_set/
fgf2induced/GeneRIF+Biological+Term+Annotations). Pearson correlation was
calculated between FGF score and BCL-2 or MCL-1 expression. Samples were
stratified into thirds based on FGF score, BCL-2 or MCL-1 expression. Survival was
analysed comparing samples with high FGF score and high expression of BCL-2 or
MCL-1 with low FGF score and low expression of BCL-2 and MCL-1. The used
code is available as a supplementary software file (Supplementary Software 1).
Wound healing experiments. For all wound repair experiments, C57BL/6 J mice
were sex and age matched (8-weeks-old) and randomly assigned to different
treatment groups. Mice were first shaved and full-thickness 1 cm2 excision wounds
were performed on the dorsal skin. Following wound infliction, mice were
euthanized with CO2 at various time points and wounded skins were embedded in
OCT for analysis. Housing, care and wounding experiments were approved by the
ethical committee of the Technion - Israel Institute of Technology
Immunofluorescence and Hematoxylin and Eosin staining. Skins frozen in OCT
were sectioned at 12 µm and fixed in 4% paraformaldehyde for 20 min at room
temperature. Samples were then blocked for 2 h, followed by incubation with
primary antibodies diluted in blocking buffer overnight at 4 °C. Following washing,
samples were incubated with secondary antibodies (Alexa Fluor 488/546/633,
Thermo) for 1 h at room temperature. The following primary antibodies were used:
MCL-1 (1:800, 5453, Cell Signaling), Ki67 (1:100, 9882, eBioscience), Mcm2 (1:500,
4461, Abcam), active ItgB1 (1:100, BD, 550531) and Alexa Fluor 568 phalloidin.
Sample analysis was performed on a Zeiss LSM 880 confocal microscope and
analysed using Zen software. Sections were first treated with Hematoxylin followed
by H2O, differentiator (0.3% alcoholic HCl), H2O, 95% EtOH, Eosin, 95% EtOH,
twice in 100% EtOH and three times in xylene before mounting in xylene based
mounting medium.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. The TCGA data used in this study are available
in the cBioPortal database under [www.cbioportal.org/study/summary?id=thym_tcga],
[https://www.cbioportal.org/study/summary?id=kich_tcga] and [https://www.cbioportal.
org/study/summary?id=ucec_tcga]. The FGF score was based on the fgf2induced dataset
from the Harmonizome [https://maayanlab.cloud/Harmonizome/gene_set/fgf2induced/
GeneRIF+Biological+Term+Annotations]. The remaining data are available within the
Article and Supplementary Information. Source data are provided with this paper.
Code availability
Bioinformatic analysis was conducted in R, the used code is available as supplementary
software file.
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